Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
Mainz Biomed B.V. (MYNZ) Stock Price & Analysis
91 Followers
MYNZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $6.00
Previous Close$0.95
Volume14.91K
Average Volume (3M)85.18K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$7.07M
Total Debt (Recent Filing)$6.39M
Price to Earnings (P/E)-0.5
Beta0.90
Next Earnings
Sep 04, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding21,165,482
10 Day Avg. Volume62,682
30 Day Avg. Volume85,184
Standard Deviation0.21
R-Squared0.00389
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-142.64
Price to Sales (P/S)22.54
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside109.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Mainz Biomed B.V. News
PremiumCompany Announcements
Mainz Biomed Secures New Funding Agreement
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsMainz announced positive topline results from its U.S. eAArly DETECT study with high sensitivity and specificity rates for colorectal cancer and advanced adenoma detection.
Market ExpansionThe high sensitivity for advanced adenomas could lead to significant market penetration in Europe and the U.S.
Product PotentialThe company's novel mRNA biomarkers approach has the potential to be best-in-class for early detection of colorectal conditions.
Bears Say
Capital ConcernsThe company may need to raise additional capital within the next 12 months, indicating a potential future dilution of shares.
Earnings ReportTop-line miss in 3Q23; total revenue was $182K, representing 88% YoY growth yet missing the projection of $400K.
Stock Price TargetDecreasing PT to $8 from $11 due to adjustments in the capital raise estimates and projected fully diluted share count.
---
Ownership Overview
0.00%
Insiders
0.09% Mutual Funds
0.53% Other Institutional Investors
99.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $0.85 and its highest was $6.00 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Currently, no data Available
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Sep 04, 2024 which is in 133 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Mainz Biomed B.V. released its earnings results on Apr 09, 2024. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.31.
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Undervalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate is -$0.23.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 16,747,460 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Mainz Biomed B.V. reported an EPS of -$0.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
---
Mainz Biomed B.V. Stock Smart Score
Company Description
Mainz Biomed B.V.
Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.
---
MYNZ Stock 12 Months Forecast
Average Price Target
$2.00
▲(109.78% Upside)
Technical Analysis
Best Analysts Covering MYNZ
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-57.68%
reiterated a buy rating 12 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.68% per trade.
---